AMNEAL PHARMS NY
GenericsAMNEAL PHARMS NY is a generic drug manufacturer focused on Cardiovascular, Gastroenterology, Infectious Disease.
AMNEAL PHARMS NY at a Glance
- Strong track record with 85% execution quality across 11 trials
- Fast trial execution (8 months median completion)
AMNEAL PHARMS NY's Key Drugs
AMNEAL PHARMS NY's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
AMNEAL PHARMS NY's Recent FDA Approvals
New NDA/BLA approvals for AMNEAL PHARMS NY over the last two years — novel drugs only, excluding generics and label supplements.
AMNEAL PHARMS NY's Therapeutic Areas
AMNEAL PHARMS NY's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Gastroenterology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AMNEAL PHARMS NY's Top Competitors
AMNEAL PHARMS NY's closest competitors by therapeutic-area and drug-target overlap include BAUSCH, Pfizer, and BAUSCH AND LOMB INC. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AMNEAL PHARMS NY Pipeline Snapshot
Active clinical trials for AMNEAL PHARMS NY across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 6/7 completed
- • Speed: 8 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1986-11-25
- Latest
- 2026-06-18
- Applications
- 50
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges